Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu JNJ-63733657 bei Teilnehmern mit früher Alzheimer-Krankheit (Autonomy)

14. Oktober 2026 aktualisiert von: Janssen Research & Development, LLC

Eine randomisierte, doppelblinde, placebokontrollierte Parallelgruppen-Multicenterstudie zur Bewertung der Wirksamkeit und Sicherheit von JNJ-63733657, einem monoklonalen Anti-Tau-Antikörper, bei Teilnehmern mit früher Alzheimer-Krankheit

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

523

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Adelaide, Australien, 5000
        • Royal Adelaide Hospital
      • Box Hill, Australien, 3128
        • Box Hill Hospital
      • Carlton, Australien, 3053
        • Neuro Trials Victoria
      • Ivanhoe, Australien, 3079
        • Austin Health
      • Malvern, Australien, 3144
        • HammondCare Neurodegenerative Clinical Trials - VIC
      • Nedlands, Australien, 6009
        • Australian Alzheimer's Research Foundation Incorporated
      • Parkville, Australien, 3050
        • Royal Melbourne Hospital
      • Bruges, Belgien, 8000
        • AZ St.-Jan Brugge-Oostende AV
      • Brussels, Belgien, 1200
        • UCL Hopital Saint-Luc
      • Edegem, Belgien, 2650
        • UZ Antwerpen
      • Ghent, Belgien, 9000
        • Universitair Ziekenhuis Gent
      • Hasselt, Belgien, 3500
        • Jessa Ziekenhuis
      • Jette, Belgien, 1090
        • UZ Brussel
      • Leuven, Belgien, 3000
        • UZ Leuven
      • Roeselare, Belgien, 8800
        • Algemeen Ziekenhuis Delta
      • Bordeaux, Frankreich, 33076
        • Hopital Pellegrin CHU Bordeaux
      • Lille, Frankreich, 59037
        • Hopital Roger Salengro - CHU Lille
      • Nantes, Frankreich, 44093
        • CHU Nantes - Hopital Nord Laënnec
      • Paris, Frankreich, 75010
        • Hopital Lariboisiere-Fernand Widal
      • Paris, Frankreich, 75013
        • Hopital Pitie Salpetriere
      • Rennes, Frankreich, 35009
        • Chu Rennes Hopital Pontchaillou
      • Rouen, Frankreich, 76031
        • Hopital Charles Nicolle
      • Toulouse, Frankreich, 31059
        • CHU Toulouse - Hôpital La Grave
      • Tours, Frankreich, 37000
        • Hôpital Bretonneau
      • Aizu-Wakamatsu, Japan, 965-8585
        • Takeda General Hospital
      • Chiba, Japan, 263-0043
        • Inage Neurology and Memory Clinic
      • Fujisawa-shi, Japan, 251-0038
        • Kawashima Neurology Clinic
      • Fukuoka, Japan, 814-0180
        • Fukuoka University Hospital
      • Hachiōji, Japan, 192-0071
        • Keikokai P-One Clinic
      • Himeji, Japan, 672-8043
        • Himeji Central Hospital Clinic
      • Kamakura-shi, Japan, 247-8533
        • Shonan Kamakura General Hospital
      • Kanzaki-gun, Japan, 842-0192
        • National Hospital Organization Hizen Psychiatric Center
      • Kawasaki, Japan, 210-0852
        • Koukan Clinic
      • Kobe, Japan, 650-0047
        • Kobe City Medical Center General Hospital
      • Kurashiki-shi, Japan, 7100813
        • Rijikai Medical Corporation Katayama Medical Clinic
      • Kurume, Japan, 830-0011
        • Kurume University Hospital
      • Kyoto, Japan, 607-8062
        • Rakuwakai Otowa Hospital
      • Kyoto, Japan, 607-8113
        • Rakuwakai Otowa Rehabilitation Hospital
      • Narashino, Japan, 275-0006
        • Saiseikai Narashino Hospital
      • Obu-shi, Japan, 474-8511
        • National Center For Geriatrics And Gerontology
      • Shinjuku-ku, Japan, 162-0053
        • Clinical Research Hospital Tokyo
      • Tokyo, Japan, 160-0023
        • Tokyo Medical University Hospital
      • Tokyo, Japan, 173-0015
        • Tokyo Metropolitan Geriatric Hospital
      • Toyonaka-shi, Japan, 560-0004
        • Nagomi Clinic
      • Toyonaka-shi, Japan, 5600004
        • Jinsenkai MI Clinic
      • Yokohama, Japan, 235-0012
        • Yokohama Brain and Spine Center
    • Ontario
      • London, Ontario, Kanada, N6C 0A7
        • Parkwood Institute
      • Peterborough, Ontario, Kanada, K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto, Ontario, Kanada, M3B 257
        • Toronto Memory Program (Neurology Research Inc.)
      • Toronto, Ontario, Kanada, M5T 2S8
        • UHN-Toronto Western Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H3A 2B4
        • McGill University
      • 's-Hertogenbosch, Niederlande, 5223 LA
        • BRC - Den Bosch
      • Amsterdam, Niederlande, 1081 GN
        • BRC - Amsterdam
      • Leeuwarden, Niederlande, 8934AD
        • QPS Netherlands
      • Zwolle, Niederlande, 8052 AZ
        • BRC Zwolle
      • Stockholm, Schweden, 14186
        • Karolinska Universitetssjukhuset
      • Algorta - Getxo, Spanien, 48993
        • Centro At. Esp. Oroitu
      • Barcelona, Spanien, 08025
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona, Spanien, 08003
        • Hosp. Del Mar
      • Barcelona, Spanien, 08028
        • Fund. Ace-Inst. Cat. Neuroc. Aplicades
      • Barcelona, Spanien, 08195
        • Idc Salud Hosp. Gral. de Catalunya
      • Lleida, Spanien, 25198
        • Hosp. Univ. Santa Maria
      • Madrid, Spanien, 28040
        • Hosp. Clinico San Carlos
      • Terrassa, Spanien, 08221
        • Hosp. Mutua Terrassa
      • Valencia, Spanien, 46026
        • Hosp. Univ. I Politecni La Fe
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • University of Alabama Birmingham
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85013
        • Dignity Health
    • California
      • Irvine, California, Vereinigte Staaten, 92614
        • Irvine Clinical Research
      • La Jolla, California, Vereinigte Staaten, 92037
        • University of California San Diego Medical Center
      • Los Angeles, California, Vereinigte Staaten, 90095
        • University of California - Los Angeles
      • Palo Alto, California, Vereinigte Staaten, 94304
        • Stanford University Medical Center
      • San Diego, California, Vereinigte Staaten, 92103
        • Pacific Research Network Prn
      • Santa Ana, California, Vereinigte Staaten, 92705
        • Syrentis Clinical Research
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06510
        • Yale University School Of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20007
        • Georgetown University Clinical Research Unit CRU
    • Florida
      • Atlantis, Florida, Vereinigte Staaten, 33462
        • JEM Research LLC
      • Delray Beach, Florida, Vereinigte Staaten, 33445
        • Brain Matters Research
      • Fort Myers, Florida, Vereinigte Staaten, 33912
        • Neuropsychiatric Research Center of SWFL
      • Jacksonville, Florida, Vereinigte Staaten, 32256
        • Clinical NeuroScience Solutions Inc
      • Jupiter, Florida, Vereinigte Staaten, 33458
        • Alphab Global Research
      • Maitland, Florida, Vereinigte Staaten, 32751
        • K2 Medical Research
      • Maitland, Florida, Vereinigte Staaten, 32751
        • Tandem Intermediate LLC
      • Merritt Island, Florida, Vereinigte Staaten, 32952
        • Merritt Island Medical Research, LLC
      • Miami, Florida, Vereinigte Staaten, 33136
        • University of Miami Miller School of Medicine
      • Miami, Florida, Vereinigte Staaten, 33137
        • Miami Jewish Health System
      • Naples, Florida, Vereinigte Staaten, 34105
        • Aqualane Clinical Research
      • Ocala, Florida, Vereinigte Staaten, 34470
        • Renstar Medical Research
      • Ocoee, Florida, Vereinigte Staaten, 34761
        • Sensible Healthcare
      • Tampa, Florida, Vereinigte Staaten, 33609
        • Axiom Clinical Research of Florida
      • Tampa, Florida, Vereinigte Staaten, 33613
        • Stedman Clinical Trials
      • Tampa, Florida, Vereinigte Staaten, 33613
        • University of South Florida - Health Byrd Alzheimer Institute
      • The Villages, Florida, Vereinigte Staaten, 32162
        • Charter Research
      • Viera, Florida, Vereinigte Staaten, 32904
        • ClinCloud Clinical Research
      • Wellington, Florida, Vereinigte Staaten, 33414
        • Alzheimers Research and Treatment Center
      • West Palm Beach, Florida, Vereinigte Staaten, 33407
        • Palm Beach Neurology and Premier Research Institute
      • Winter Park, Florida, Vereinigte Staaten, 32789
        • Conquest Research
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30329
        • The Emory Clinic
      • Decatur, Georgia, Vereinigte Staaten, 30030
        • Sandhill Research
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60640
        • Great Lakes Clinical Trials
      • Elk Grove Village, Illinois, Vereinigte Staaten, 60007
        • Alexian Brothers Medical Center - Neuroscience Research Institute
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Indiana University
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital
      • Braintree, Massachusetts, Vereinigte Staaten, 02184
        • Anil Nair dba Alzheimer's Disease Center
    • Mississippi
      • Hattiesburg, Mississippi, Vereinigte Staaten, 39401
        • Hattiesburg Clinic
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University School Of Medicine
    • New Jersey
      • Mount Arlington, New Jersey, Vereinigte Staaten, 07856
        • NeuroCognitive Institute
      • Princeton, New Jersey, Vereinigte Staaten, 08540
        • Princeton Medical Institute
      • Toms River, New Jersey, Vereinigte Staaten, 08755
        • Advanced Memory Research Institute of NJ
    • New York
      • Albany, New York, Vereinigte Staaten, 12208
        • Neurological Associates of Albany, PC
      • East Syracuse, New York, Vereinigte Staaten, 13057
        • Velocity Clinical Research
      • New York, New York, Vereinigte Staaten, 10016
        • New York University Medical Center
    • North Carolina
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27157
        • Wake Forest Health Sciences
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Cleveland Clinic Lou Revo Center for Brain Health
      • Columbus, Ohio, Vereinigte Staaten, 43221
        • Wexner Medical Center at the Ohio State University
    • Pennsylvania
      • Plymouth Meeting, Pennsylvania, Vereinigte Staaten, 19462
        • Keystone Clinical Studies LLC
    • Rhode Island
      • Providence, Rhode Island, Vereinigte Staaten, 02906
        • Brown University School of Medicine
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77054
        • The University of Texas Health Science Center at Houston
    • Vermont
      • Bennington, Vermont, Vereinigte Staaten, 05201
        • Memory Clinic Inc
    • Virginia
      • Charlottesville, Virginia, Vereinigte Staaten, 22903
        • University of Virginia
      • Bath, Vereinigtes Königreich, BA1 3NG
        • Royal United Hospital
      • London, Vereinigtes Königreich, W6 8RF
        • Charing Cross Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

55 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (>=) 0.5 at screening
  • Participants must have positive tau PET results
  • Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
  • Have a designated study partner who has adequate literacy to participate and be judged to have high likelihood of completing the study with the participant
  • Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention

Exclusion Criteria:

  • Participants with CDR GS >=2 at predose baseline Clinical Dementia Rating (CDR) administration
  • Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera[etc])
  • Geriatric Depression Scale (GDS) 30 score greater than (>) 12
  • Hachinski Ischemic Scale (HIS) >4
  • Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 2 months; that is, doses of chronic medications that effect the CNS should be stable for at least 2 months before the start of screening. If a participant has recently stopped a chronic medication that effects the CNS, he or she must have discontinued treatment at least 2 months before the start of screening. Chronic use of benzodiazepines is not permitted

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: JNJ-63733657 Low-dose

Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.

JNJ-63733657 low or high dose will be administered by IV infusion.

Experimental: JNJ-63733657 High-dose

Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.

JNJ-63733657 low or high dose will be administered by IV infusion.

Placebo-Komparator: Placebo

Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period.

Placebo matching to JNJ-63733657 will be administered by IV infusion.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104
Zeitfenster: Baseline (Day 1), Week 104

The iADRS-MCI was a composite measure of cognition and function. It was originally developed as a combination of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) 14-item cognition subscale and the instrumental activities of daily living (ADL) items from the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale. It was calculated as a linear combination of total scores of the 2 individual components. The iADRS-MCI total score was derived as a combination of the ADAS-Cog13 total score (ranging from 0 to 85, with higher scores indicating worse cognitive performance) and the ADCS-ADL-MCI total score (ranging from 0 to 53, with lower scores indicating worse daily function). Therefore, the iADRS-MCI total score was calculated as [-1(ADAS-Cog13 score)+85] + ADCS-ADL-MCI score, ranging from 0 to 138, with lower scores indicating worse performance.

Baseline (Day 1), Week 104

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive, 13-item Version (ADAS-Cog13) Total Score at Week 104
Zeitfenster: Baseline (Day 1), Week 104

The ADAS-Cog was a rater administered instrument that was designed to assess the severity of dysfunction in cognition characteristic of persons with Alzheimer's Disease (AD). The ADAS-Cog13 item scale includes all items from the original ADAS-Cog11 (consisting of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities, often referred to as the core symptoms of AD) in addition of number cancellation task and a delayed free recall task, for a total of 85 points (0 to 85), with higher scores indicating worse cognitive performance.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score at Week 104
Zeitfenster: Baseline (Day 1), Week 104

The ADCS-ADL-MCI was a functional measure based on information provided by the study partner that describes the performance of participants in several activities of daily living. The ADCS-ADL-MCI scale consists of 17 instrumental items (example; shopping, preparing meals, using household appliances, etc) and 1 basic item (getting dressed). The ADCS-ADL-MCI scale version used in this study comprises 24 items of which 18 items are used for the standard analysis. The total score ranges from 0 to 53 with higher scores indicating less impairment. A positive change from baseline indicates healthy functioning while a negative change from baseline indicates a decline in independent functioning.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at Week 88
Zeitfenster: Baseline (Day 1), Week 88

The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. The RBANS total scale Index score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160. Higher scores indicated better performance.

Baseline (Day 1), Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 5 Individuals RBANS Indices at Week 88
Zeitfenster: Baseline (Day 1), Week 88

The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the sum of index scores was converted to an RBANS total scale index score via a mapping table. The RBANS Total Scale Index Score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160 each of the index scores. Higher scores indicated better performance.

Baseline (Day 1), Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 12 Subtests Comprising the RBANS at Week 88
Zeitfenster: Baseline (Day 1), Week 88

The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning [0-40] and story memory [0-24]), visuospatial/constructional (figure copy [0-20] and line orientation [0-20]), language (picture naming [0-10] and semantic fluency [0-40]), attention (digit span [0-16] and coding [0-89]) and delayed memory (list recall [0-10], list recognition [0-20], story recall [0-12], and figure recall [0-20]). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an SD of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. Scores range from 40 to 160. Higher scores indicated better performance.

Baseline (Day 1), Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at Week 104
Zeitfenster: Baseline (Day 1), Week 104

The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the CDR interview. The CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-SB was the sum of the 6 domains which ranged from 0 (least impairment) to 18 (severe impairment). Higher scores indicated worse disease state.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104
Zeitfenster: Baseline (Day 1), Week 104

The NPI was a measure of psychobehavioral disturbances, assessing the frequency and severity of disturbances in 12 domains, based on a caregiver interview. For each domain, there was also an assessment of caregiver burden. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being the product of the frequency and severity scores, such that each domain was scored from 1 to 12. The NPI total score was the sum of the 12 domain scores, ranged from 0 (best) to 144 (worst). Higher score indicated worst psychobehavior.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Percentage of Participants With Progression From Clinical Dementia Rating-Global Score (CDR-GS) 0 to 0.5 or Higher, 0.5 to 1 or Higher, and 1 to 2 or Higher
Zeitfenster: From baseline (Day 1) up to Week 104

Percentage of participants with progression from CDR-GS 0 to 0.5 or higher, 0.5 to 1 or higher, and 1 to 2 or higher was reported. The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: (1) memory, (2) orientation, (3) judgment and problem solving, (4) involvement in community affairs, (5) home and hobbies, and (6) personal care based on the CDR interview. CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-GS was derived based on an algorithm and was scored of 0 (normal), 0.5 (very mild dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). Score ranges from 0 to 3 and a high score on CDR-GS indicated a high disease severity.

From baseline (Day 1) up to Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Brain Tau Burden as Measured by Tau Positron Emission Tomography (PET) at Week 104
Zeitfenster: Baseline (Day 1), Week 104

Change from baseline in brain tau burden (tau naive composite Region of interest [ROI] standardized uptake value ratio [SUVR], cerebral cortex ROI SUVR, meta temporal ROI SUVR, spatial progression of tauopathy [SPOT] volume over cerebral cortex ROI) as measured by tau PET was reported. For tau naive ROI method, tau PET brain scans were assessed to measure change in SUVR over regions without evidence of tau burden at baseline (that is, within 1 standard deviation of a cognitively normal amyloid negative reference population). For SPOT method, tau PET brain scans were assessed to quantify extent of spread of tau by measuring difference in volume of elevated tau PET burden (defined as exceeding an SUVR threshold of 1.2) in cerebral cortex brain region at follow up versus that at baseline. Tau PET brain scans were assessed to measure spread of tau tangles using SUVR in cerebral cortex, meta temporal brain region, respectively.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Cerebrospinal Fluid (CSF) Concentrations of Total, Free, and Bound p217+Tau Fragments at Week 104
Zeitfenster: Baseline (Day 1), Week 104

Change from baseline in CSF concentration of total, free, and bound p27+tau fragments at Week 104 was reported.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Cerebrospinal Fluid (CSF) Concentrations of JNJ-63733657
Zeitfenster: Weeks 52, 104, and 208

CSF concentration of JNJ-63733657 was reported.

Weeks 52, 104, and 208
Double-blind (DB) Treatment Period: Serum Concentrations of JNJ-63733657
Zeitfenster: Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180

Serum concentration of JNJ-63733657 was reported.

Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent JNJ-63733657 Antidrug Antibodies (ADAs) in Serum
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent JNJ-63733657 ADA in serum was reported. Any ADAs occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. Participants with treatment-emergent antibodies to JNJ-63733657 included participants with treatment-induced antibodies to JNJ-63733657 and treatment-boosted antibodies to JNJ- 63733657.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Any SAE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AESIs were collected in the eCRF and examined separately, grouped in the following categories including: hepatobiliary disorders/Liver enzyme abnormality, and Infusion-related reactions. Any AESI occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants Who Discontinued Study Treatment Due to AEs
Zeitfenster: Baseline (Day 1) up to Week 232

Number of participants who discontinued the study treatment due to AE was reported.

Baseline (Day 1) up to Week 232
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead Electrocardiogram (ECG) Parameter: ECG Mean Heart Rate Supine
Zeitfenster: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180

Change from baseline in 12-lead ECG parameter (ECG mean heart rate supine) was reported.

Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval, QTcL Interval, and RR Interval
Zeitfenster: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180

Change from baseline in 12-lead ECG parameter (PR interval, QRS duration, QT interval, QTcB interval, QTcF interval, QTcL interval and RR interval) was reported.

Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormalities in Laboratory Parameters
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent abnormalities in laboratory parameters (hematology, chemistry and urinalysis) were reported. Laboratory abnormalities meeting with lower limit of the normal range (LLN) and upper limit of the normal range (ULN) was reported. Any laboratory abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Neurological Examination
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent abnormal findings in neurological examination (mental state, cranial nerves, motor ability: strength, tone, involuntary movements, coordination: finger-to-nose, gai, postural reflexes, sensation: proprioception, cold, light touch, deep tendon reflexes) was reported. Abnormalities in neurological examination was determined by the investigator. Any neurological abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Physical Examination
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent abnormal findings in physical examination (general appearance, skin, eye, ear, nose, throat, heart, head, neck, thyroid, chest, lung, abdomen, musculoskeletal, breast, neurological) was reported. Abnormal findings in physical examination was determined by the investigator. Any physical abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Potentially Clinically Significant Vital Signs
Zeitfenster: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent potentially clinically significant vital signs including systolic blood pressure (standing and supine: less than (<) 90 millimeters of mercury (mmHg) and greater than (>) 180 mmHg), diastolic blood pressure (standing and supine: <50 mmHg and >105 mmHg), pulse (<45 bpm to >120 bpm), temperature (<35 degree Celsius and >38 degree Celsius) and weight (decrease of >=10% relative to baseline and increase of >=10% relative to baseline) were reported. Any clinically significant vital sign occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Brain Magnetic Resonance Imaging (MRI) Safety Findings
Zeitfenster: From Day 1 up to Week 245

Number of participants with brain MRI safety findings was reported. MRI safety-related observations from the central imaging vendor including vasogenic edema, cerebral macrohemorrhages, cerebral superficial siderosis and other findings was reported.

From Day 1 up to Week 245
Double-blind (DB) Treatment Period: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)
Zeitfenster: Baseline (Day 1) up to Week 245

C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior.

Baseline (Day 1) up to Week 245

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

6. Januar 2021

Primärer Abschluss (Tatsächlich)

17. Oktober 2025

Studienabschluss (Tatsächlich)

3. März 2026

Studienanmeldedaten

Zuerst eingereicht

5. November 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. November 2020

Zuerst gepostet (Tatsächlich)

6. November 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CR108832
  • 2020-000116-30 (EudraCT-Nummer)
  • 63733657ALZ2002 (Andere Kennung: Janssen Research & Development, LLC)
  • 2022-501188-42-00 (Registrierungskennung: EUCT number)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren